[ad_1]
Allarity Therapeutics, Inc.
Press launch
Cambridge, MA U.S.A. (August 26, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical firm growing novel oncology therapeutics along with drug-specific DRP® companion diagnostics for customized most cancers care, at this time introduced that on August 23, 2022, it acquired a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with necessities of Nasdaq Listing Rule 5250(c)(1) because of not having well timed filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, with the Securities and Exchange Commission (“SEC”).
This notification has no instant impact on the itemizing of the Company’s frequent inventory on the Nasdaq. However, if the Company fails to well timed regain compliance with the Nasdaq Listing Rule, the Company’s frequent inventory might be topic to delisting from Nasdaq.
Under the Nasdaq guidelines, the Company has 60 calendar days to undergo Nasdaq a plan to regain compliance with the Nasdaq Listing Rule. If Nasdaq accepts the Company’s plan, then Nasdaq could grant the Company as much as 180 days from the prescribed due date for submitting the Form 10-Q to regain compliance. If Nasdaq doesn’t settle for the Company’s plan, then the Company can have the chance to enchantment that call to a Nasdaq Hearings Panel. The Company intends to file its Form 10-Q as quickly as practicable.
About Allarity Therapeutics
Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops medication for customized therapy of most cancers guided by its proprietary and extremely validated companion diagnostic expertise, the DRP® platform. The Company has a mature portfolio of three drug candidates: stenoparib, a PARP inhibitor in Phase 2 improvement for ovarian most cancers; dovitinib, a post-Phase 3 pan-tyrosine kinase inhibitor; and IXEMPRA® (Ixabepilone), a microtubule inhibitor accredited within the U.S. for the therapy of second-line metastatic breast most cancers and in Phase 2 improvement in Europe for a similar indication. Additionally, the Company has rights in two secondary belongings: 2X-111, a liposomal formulation of doxorubicin in Phase 2 improvement for metastatic breast most cancers and/or glioblastoma multiforme (GBM), which is the topic of discussions for a restructured out-license to Smerud Medical Research International AS; and LiPlaCis®, a liposomal formulation of cisplatin and its accompanying DRP®, being developed by way of a partnership with Chosa ApS, an affiliate of Smerud Medical Research International, for late-stage metastatic breast most cancers. The Company is headquartered within the United States and maintains an R&D facility in Hoersholm, Denmark. For extra data, please go to the Company’s web site at www.Allarity.com.
Story continues
About the Drug Response Predictor – DRP® Companion Diagnostic
Allarity makes use of its drug-specific DRP® to pick these sufferers who, by the genetic signature of their most cancers, are discovered to have a excessive probability of responding to the particular drug. By screening sufferers earlier than therapy, and solely treating these sufferers with a sufficiently excessive DRP® rating, the therapeutic response fee may be considerably elevated. The DRP® technique builds on the comparability of delicate vs. resistant human most cancers cell traces, together with transcriptomic data from cell traces mixed with scientific tumor biology filters and prior scientific trial outcomes. DRP® is predicated on messenger RNA from affected person biopsies. The DRP® platform has confirmed its potential to offer a statistically vital prediction of the scientific consequence from drug therapy in most cancers sufferers in 37 out of 47 scientific research that had been examined (each retrospective and potential), together with ongoing, potential Phase 2 trials of Stenoparib and IXEMPRA®. The DRP® platform, which can be utilized in all most cancers varieties and is patented for greater than 70 anti-cancer medication, has been extensively revealed in peer reviewed literature.
Follow Allarity on Social Media
Facebook: https://www.fb.com/AllarityTx/
LinkedIn: https://www.linkedin.com/firm/allaritytx/
Twitter: https://twitter.com/allaritytx
Forward-Looking Statements
This press launch comprises “forward-looking statements” inside the that means of the Private Securities Litigation Reform Act of 1995. Forward-looking statements present Allarity’s present expectations or forecasts of future occasions. The phrases “anticipates,” “imagine,” “proceed,” “might,” “estimate,” “count on,” “intends,” “could,” “may,” “plan,” “attainable,” “potential,” “predicts,” “challenge,” “ought to,” “would” and comparable expressions could establish forward-looking statements, however the absence of those phrases doesn’t imply {that a} assertion is just not forward-looking. These forward-looking statements embody, however usually are not restricted to, statements associated to the Company’s potential to regain compliance with the Nasdaq Listing Rule, statements referring to the timing of the submitting of the Form 10-Q with the SEC, statements associated to the anticipated availability capital to fund its anticipated scientific trials, statements associated to advancing dovitinib together with one other therapeutic candidate or different accredited drug, any statements associated to ongoing scientific trials for stenoparib as a monotherapy or together with one other therapeutic candidate for the therapy of superior ovarian most cancers, or ongoing scientific trials (in Europe) for IXEMPRA® for the therapy of metastatic breast most cancers, and statements referring to the effectiveness of the Company’s DRP® companion diagnostics platform in predicting whether or not a selected affected person is probably going to reply to a selected drug. Any forward-looking statements on this press launch are based mostly on administration’s present expectations of future occasions and are topic to a lot of dangers and uncertainties that would trigger precise outcomes to vary materially and adversely from these set forth in or implied by such forward-looking statements. These dangers and uncertainties embody, however usually are not restricted to, the chance that outcomes of a scientific examine don’t essentially predict remaining outcomes and that a number of of the scientific outcomes could materially change following extra complete critiques of the info, and as extra affected person knowledge turn into obtainable, the chance that outcomes of a scientific examine are topic to interpretation and extra analyses could also be wanted and/or could contradict such outcomes, the receipt of regulatory approval for dovitinib or any of our different therapeutic candidates or, if accredited, the profitable commercialization of such merchandise, the chance of cessation or delay of any of the continuing or deliberate scientific trials and/or our improvement of our product candidates, the chance that the outcomes of beforehand carried out research won’t be repeated or noticed in ongoing or future research involving our therapeutic candidates, and the chance that the present COVID-19 pandemic will impression the Company’s present and future scientific trials and the timing of the Company’s preclinical research and different operations. For a dialogue of different dangers and uncertainties, and different essential elements, any of which might trigger our precise outcomes to vary from these contained within the forward-looking statements, see the part entitled “Risk Factors” in our Form S-1 registration assertion on file with the Securities and Exchange Commission, obtainable on the Securities and Exchange Commission’s web site at www.sec.gov, and in addition to discussions of potential dangers, uncertainties and different essential elements within the Company’s subsequent filings with the Securities and Exchange Commission. All data on this press launch is as of the date of the discharge, and the Company undertakes no responsibility to replace this data until required by regulation.
###
Company Contact:
Thomas Jensen
Senior V.P. of Investor Relations
investorrelations@allarity.com
Investor Relations:
Chuck Padala
LifeSci Advisors
+1 1 (646) 627-8390
chuck@lifesciadvisors.com
U.S. Media Contact:
Mike Beyer
Sam Brown, Inc.
+1 (312) 961-2502
mikebeyer@sambrown.com
EU Media Contact:
Thomas Pedersen
Carrotize PR & Communications
+45 6062 9390
tsp@carrotize.com
Attachment
[ad_2]
Source link
#Allarity #Therapeutics #Receives #Nasdaq #Notification #NonCompliance #Listing #Rule #5250c1